SARS‐CoV‐2 PL<sup>pro</sup> Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment-Reference-Cited by-同舟云学术

SARS‐CoV‐2 PL^pro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment

Published:2024-08-05 Issue: Volume: Page:
ISSN:2191-1363
Container-title:ChemistryOpen
language:en
Short-container-title:ChemistryOpen

Author:

Protić Sara¹,Crnoglavac Popović Milica¹,Kaličanin Nevena²,Prodanović Olivera³,Senćanski Milan⁴⁵,Milićević Jelena⁴,Stevanović Kristina⁴,Perović Vladimir⁴,Paessler Slobodan⁶⁷,Prodanović Radivoje¹,Glišić Sanja⁴

Affiliation:

1. Faculty of Chemistry University of Belgrade Studentski Trg 12–16 Belgrade Serbia

2. Institute of Chemistry Technology and Metallurgy University of Belgrade Njegoševa 12 Belgrade Serbia

3. Institute for Multidisciplinary Research University of Belgrade Kneza Višeslava 1 Belgrade Serbia

4. Laboratory of Bioinformatics and Computational Chemistry Institute of Nuclear Sciences Vinca National Institute of the Republic of Serbia University of Belgrade Mike Petrovica Alasa 12–14 Belgrade Serbia

5. Laboratory for Plant Molecular Biology Institute of Molecular Genetics and Genetic Engineering University of Belgrade Vojvode Stepe 444a Belgrade Serbia

6. Department of Pathology University of Texas Medical Branch Galveston Texas United States

7. Institute for Human Infections and Immunity University of Texas Medical Branch Galveston Texas United States

Abstract

AbstractThe emergence of drug‐resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID‐19 pandemic. While de novo drug development is a time‐consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS‐CoV‐2 papain‐like protease inhibitor. This study extends those findings by investigating fidaxomicin‘s antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS‐CoV‐2, given its promising in vitro antiviral activity and favorable safety profile.

Funder

Science Fund of the Republic of Serbia

Publisher

Wiley

Reference29 articles.

1. Therapeutic strategies for COVID-19: progress and lessons learned

2. Nirmatrelvir Plus Ritonavir: First Approval

3. The role of antiviral treatment in the COVID-19 pandemic

4. Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management